Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 1,857.50 | 1,947.55 | 1,202.46 | - | - |
Total Expenses | 1,557.01 | 1,686.78 | 1,047.08 | 0 | - |
Profit Before Tax | 300.49 | 260.77 | 155.38 | -0 | - |
Profit After Tax | 216.90 | 193.49 | 122.25 | -0 | - |
Operating Profit after Depreciation | 317.71 | 281.83 | 167.34 | -0 | - |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 1,091.75 | 965.50 | 804.23 | - | - |
Total Non Current Assets | 1,236.46 | 1,081.02 | 1,011.75 | - | - |
Total Current Assets | 1,345.64 | 1,163.01 | 1,028.15 | 0.25 | - |
TOTAL ASSETS | 2,582.11 | 2,244.02 | 2,039.90 | 0.25 | - |
Total Shareholder's Fund | 1,757.04 | 1,558.49 | 1,386.48 | 0.23 | - |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 216.35 | 250.12 | -43.70 | - | - |
Net Cash used in Investing Activities | -214.56 | -157.80 | -138.74 | - | - |
Net Cash used in Financing Activities | 9.72 | -163.46 | 260.38 | - | - |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 1,513.14 | 1,512.53 | 943.53 | - | - |
Total Expenses | 1,238.62 | 1,279.17 | 809.81 | 0 | 0.02 |
Profit Before Tax | 274.52 | 233.36 | 133.73 | -0 | -0.02 |
Profit After Tax | 200.65 | 171.73 | 106.73 | -0 | -0.02 |
Operating Profit after Depreciation | 291.15 | 253.84 | 145.07 | -0 | -0.02 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 1,011.75 | 888.06 | 723.26 | - | - |
Total Non Current Assets | 1,162.85 | 1,010.15 | 936.56 | - | - |
Total Current Assets | 1,134.06 | 966.22 | 890.27 | 0.25 | 0.25 |
TOTAL ASSETS | 2,296.91 | 1,976.37 | 1,826.83 | 0.25 | 0.25 |
Total Shareholder's Fund | 1,621.46 | 1,438.58 | 1,284.28 | 0.23 | 0.23 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 183.69 | 215.88 | -64.84 | - | -0.02 |
Net Cash used in Investing Activities | -184.40 | -115.55 | -133.54 | - | - |
Net Cash used in Financing Activities | 4.40 | -156.53 | 254.63 | - | 0.27 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 537.78 | 458.03 | 555.49 | 505.77 | 448.69 |
Total Expenses | 409.17 | 364.36 | 459.03 | 388.26 | 353.02 |
Profit Before Tax | 100.63 | 71.76 | 73.68 | 95.74 | 73.81 |
Profit After Tax | 73.99 | 54.62 | 55.45 | 65.25 | 52.76 |
Operating Profit after Depreciation | 133.64 | 98.15 | 98.68 | 119.54 | 97.06 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 470.95 | 377.29 | 393.49 | 414.82 | 373.03 |
Total Expenses | 355.96 | 292.52 | 309.83 | 307.48 | 284.75 |
Profit Before Tax | 96.19 | 63.44 | 63.23 | 91.29 | 67.44 |
Profit After Tax | 73.52 | 47.84 | 47.14 | 63.02 | 48.19 |
Operating Profit after Depreciation | 126.93 | 87.72 | 85.77 | 113.03 | 88.74 |
₹2.5/Share
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Aarti Pharmalabs Ltd | ₹807.70 | ₹7,319.86 |
Sun Pharmaceuticals Industries Ltd | ₹1,701.55 | ₹4,08,258.84 |
Divis Laboratories Ltd | ₹5,835.60 | ₹1,54,916.84 |
Cipla Ltd | ₹1,482.20 | ₹1,19,704.55 |
Torrent Pharmaceuticals Ltd | ₹3,046.30 | ₹1,03,096 |
Dr Reddys Laboratories Ltd | ₹1,197.85 | ₹99,951.47 |
Aarti Pharmalabs surged 14.32% to Rs 728.85 after the company's consolidated net profit jumped 40.2% to Rs 73.99 crore in Q3 FY25 as against Rs 52.76 crore posted in Q3 FY24.
06 Feb 2025, 11:08 am
Of Rs 2.5 per share
05 Feb 2025, 08:52 pm
On 5 February 2025
28 Jan 2025, 03:03 pm
03 Jan 2025, 06:18 pm
W.e.f. 30 October 2024
28 Oct 2024, 05:31 pm